Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...

Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, announced an interim data readout of the phase 1/2a studies of Radspherin for the treatment ...

Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced ...

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...